

Ex-vivo / in-vitro studies on immune-activators and blockers in hidradenitis suppurativa

Published: 11-02-2020

Last updated: 10-04-2024

To investigate the functional implication of bacteria, cigarette smoke components and adipokines in HS pathology by analyzing the cytokine profiles and the antimicrobial peptide profiles in skin and peripheral blood samples of patients with HS and...

Ethical review	Not approved
Status	Will not start
Health condition type	Other condition
Study type	Observational invasive

Summary

ID

NL-OMON49375

Source

ToetsingOnline

Brief title

Immune activation in hidradenitis suppurativa

Condition

- Other condition

Synonym

acne inversa, verneuil's disease

Health condition

De proefpersonen fungeren als de controle groep van patienten met de huidziekte hidradenitis suppurativa.

Research involving

Human

Sponsors and support

Primary sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Hidradenitis suppurativa, Immune activation, Immune response

Outcome measures

Primary outcome

The main study parameter is the difference of immune response to above mentioned HS triggering factors, for example the cytokine/antimicrobial profile after microbial exposure in HS patients compared to healthy controls.

Secondary outcome

N.A.

Study description

Background summary

HS is considered a complex disease involving several factors. The clinical presentation of HS appears reminiscent of bacterial infection. However, the role of these bacterial species is poorly understood and is far from resolved. Other important associated factors are smoking and obesity. In order to gain more insights into the pathogenesis of HS, especially the interaction between commensal flora, cigarette smoke components, adipokines and the immune system further exploration is required

Study objective

To investigate the functional implication of bacteria, cigarette smoke components and adipokines in HS pathology by analyzing the cytokine profiles and the antimicrobial peptide profiles in skin and peripheral blood samples of patients with HS and healthy controls.

Study design

Explorative and experimental study

Study burden and risks

The subject will not directly benefit from this research, but participation contributes to increase the knowledge about HS and subsequently improving treatment and care.

Contacts

Public

Erasmus MC, Universitair Medisch Centrum Rotterdam

Dr. Molewaterplein 40

Rotterdam 3015 GD

NL

Scientific

Erasmus MC, Universitair Medisch Centrum Rotterdam

Dr. Molewaterplein 40

Rotterdam 3015 GD

NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Inclusion criteria cases * HS patients

- Participating in HiScreen Biobank

- Informed consent available for blood samples

Inclusion criteria controls

- Adult (> 18 years old) patients not suffering from HS.
- Competent and willing to provide informed consent.

Exclusion criteria

Exclusion criteria HS patients

- <18 years of age
- use of systemic or local antibiotics in the past 2 weeks
- use of any other medication potentially affecting the cytokine/antimicrobial profiles

-

Exclusion criteria controls

- <18 years of age
- known with hidradenitis suppurativa
- use of systemic and local antibiotics in the past 2 weeks
- use of any other medication potentially affecting the cytokine/antimicrobial profiles
- pregnant women

Exclusion criteria controls

- <18 years of age
- known with hidradenitis suppurativa
- use of systemic and or local antibiotics in the past 2 weeks
- use of any other medication potentially affecting the cytokine/antimicrobial profiles
- no relatives with HS
- pregnant women

Study design

Design

Study type:	Observational invasive
Intervention model:	Other
Allocation:	Non-randomized controlled trial
Masking:	Open (masking not used)

Control:	Active
Primary purpose:	Other

Recruitment

NL	
Recruitment status:	Will not start
Enrollment:	20
Type:	Anticipated

Ethics review

Not approved	
Date:	11-02-2020
Application type:	First submission
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL71699.078.19